Related Experiment Video
Updated: Jan 11, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[A Clinical Study of Children with SIL-TAL1-Positive Acute T-Lymphoblastic Leukemia]
Yu-Juan Xue1, Yu Wang1, Le-Ping Zhang1
1Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Insights
Children with SIL-TAL1-positive T-cell acute lymphoblastic leukemia (T-ALL) have higher white blood cell counts but similar treatment outcomes. However, younger children (<10 years) with SIL-TAL1+ T-ALL show superior long-term survival rates.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Biology
Objective:
To explore the clinical characteristics and prognosis of children with SIL-TAL1-positive T-cell acute lymphoblastic leukemia ( SIL-TAL1+ T-ALL).
Methods:
The clinical data of 110 children with newly diagnosed T-ALL admitted to the pediatric department of our hospital from January 2010 to December 2018 were reviewed to compare the clinical characteristics, treatment response and prognosis between SIL-TAL1+ group and SIL-TAL1-group.
Results:
Among the 110 children with T-ALL, 25 cases (22.7%) were in the SIL-TAL1+ group and 85 cases (77.3%) in the SIL-TAL1- group. The white blood cell (WBC) count in the SIL-TAL1+ group was significantly higher than that in the SIL-TAL1- group (P < 0.05), while the other clinical characteristics and treatment response were not significantly different between the two groups. The 5-year overall survival (OS) rates of SIL-TAL1+ group and SIL-TAL1- group were 80.0% and 75.5%, and 5-year disease-free survival (DFS) rates were 76.0% and 72.9%, respectively. There were no significant differences in OS rate and DFS rate between the two groups ( P >0.05). In children aged < 10 years, the 5-year OS rate of SIL-TAL1+ group and SIL-TAL1- group was 100% and 75.1%, respectively, and the difference between the two groups was statistically significant (P < 0.05).
Conclusion:
Although the WBC level is significantly higher in children with SIL-TAL1+ T-ALL than that in those with SIL-TAL1- T-ALL, the treatment efficacy is similar between the two groups. In children aged < 10 years, the longterm survival rate is superior in the SIL-TAL1+ group.
